EU MDR Three Years In: Winners, Losers, and the Data Behind the Transition

The May 2025 expiry of the final EU MDR transitional provisions for legacy devices represented the true end of a regulatory era that began with the regulation's entry into force in 2017. Our dataset of EUDAMED registrations, notified body certificates, and field safety notices now contains enough post-transition signal to draw meaningful conclusions about market structure effects. The headline finding is stark: across Class IIb implantables, the total number of active EU certificates declined by approximately 18% between Q3 2024 and Q1 2026, with the steepest attrition in older electrophysiology leads, neurostimulator accessories, and legacy surgical robotics components.

Notified body capacity remained the central structural constraint throughout the transition period. Bodies designated under MDR numbered just 46 at peak — less than half the number operating under MDD — and several of the largest bodies implemented hard submission caps in 2024 that effectively created two-year backlogs for complex Class III dossiers. Our data shows that manufacturers with existing relationships at BSI, TÜV SÜD, and SGS secured certificate renewals at a median of 14 months faster than those who were forced to establish new notified body relationships mid-transition. This relationship premium translated directly into market access continuity.

The winners in the post-MDR landscape are disproportionately large, vertically integrated manufacturers with dedicated regulatory affairs organizations capable of managing the clinical evidence burden MDR imposes. Medtech SMEs — particularly those headquartered outside the EU — have withdrawn a measurable number of SKUs from the European market rather than invest in MDR-compliant clinical evaluation reports for low-revenue product lines. This SKU rationalization is already showing up in procurement data from several national health systems, with particular supply pressure noted in niche surgical instruments and single-use endoscopy accessories.

Looking ahead, the European Commission's targeted amendments to MDR — focused on orphan device provisions and the IVDR transition — signal a more adaptive regulatory posture from Brussels than the original regulation suggested. Manufacturers that successfully navigated the MDR transition have accumulated hard-won process capital in clinical evidence generation, PMS system design, and technical file architecture. That capital is now a competitive moat. The question for the next phase is whether notified body capacity will expand quickly enough to support the wave of new product introductions that have been deferred while transition resources were consumed.